ProPhase Labs Q2 revenue falls 81% to $2.5M; net loss $(0.33) per share; eyes H2 growth

ProPhase Labs, Inc.

2024-Q2 EPS reported -$0.67 revenue$6,108,000

Net revenue $2.5M vs $13.2M YoY; net loss $6.2M ($0.33 per share) vs $3.4M ($0.20) in Q2 2023.
COVID-19 testing revenue zero (126K tests in prior year); overall gross margin negative 19.2%.
Pharmaloz projects $14-16M revenue and >$5M pre-tax profit over next 12 months; exploring potential sale.
Nebula Genomics launching revamped DTC product 'DNA Complete' with influencer marketing campaign.
Cash and equivalents $2.4M; working capital $16.1M; expects significant sequential revenue growth in Q3 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.